Role of drug metabolism in drug discovery and development

被引:144
作者
Kumar, GN [1 ]
Surapaneni, S [1 ]
机构
[1] Amgen Inc, Dept Pharmacokinet & Drug Metab, Thousand Oaks, CA 91320 USA
关键词
drug metabolism; drug discovery; cytochrome P450; drug-drug interactions;
D O I
10.1002/med.1016
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Metabolism by the host organism is one of the most important determinants of the pharmacokinetic profile of a drug. High metabolic lability usually leads to poor bioavailability and high clearance. Formation of active or toxic metabolites will have an impact on the pharmacological and toxicological outcomes. There is also potential for drug-drug interactions with coadministered drugs due to inhibition and/or induction of drug metabolism pathways. Hence, optimization of the metabolic liability and drug-drug interaction potential of the new chemical entities are some of the most important steps during the drug discovery process. The rate and site(s) of metabolism of new chemical entities by drug metabolizing enzymes is amenable to modulation by appropriate structural changes. Similarly, the potential for drug-drug interactions can also be minimized by appropriate structural modifications to the drug candidate. However, the optimization of the metabolic stability and drug-drug interaction potential during drug discovery stage has been largely by empirical methods and by trial and error. Recently, a lot of effort has been applied to develop predictive methods to aid the optimization process during drug discovery and development. This article reviews the role of drug metabolism in drug discovery and development. (C) 2001 John Wiley & Sons, Inc.
引用
收藏
页码:397 / 411
页数:15
相关论文
共 50 条
  • [41] An overview of immunotoxicity in drug discovery and development
    Nandre, Rahul M.
    Terse, Pramod S.
    TOXICOLOGY LETTERS, 2025, 403 : 66 - 75
  • [42] Mathematical modeling in drug discovery and development
    Miftahof, R.
    Akhmadeev, N.
    MODELLING IN MEDICINE AND BIOLOGY VII, 2007, 12 : 319 - +
  • [43] Proteomics in biomarker discovery and drug development
    He, QY
    Chiu, JF
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2003, 89 (05) : 868 - 886
  • [44] Fluorination methods for drug discovery and development
    Richardson, Paul
    EXPERT OPINION ON DRUG DISCOVERY, 2016, 11 (10) : 983 - 999
  • [45] Role of Hepatic Drug Transporters in Drug Development
    Liu, Houfu
    Sahi, Jasminder
    JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 56 : S11 - S22
  • [46] Prediction of ARA/PPI Drug-Drug Interactions at the Drug Discovery and Development Interface
    Dodd, Stephanie
    Kollipara, Sivacharan
    Sanchez-Felix, Manuel
    Kim, Hyungchul
    Meng, Qingshuo
    Beato, Stefania
    Heimbach, Tycho
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2019, 108 (01) : 87 - 101
  • [47] Nonprofit model for drug discovery and development
    Frank, Gregory Daniel
    Jong, Ling
    Collins, Nathan
    Spack, Edward G.
    DRUG DEVELOPMENT RESEARCH, 2007, 68 (04) : 186 - 196
  • [48] Natural products as drug leads: exploring their potential in drug discovery and development
    Singh, Kuldeep
    Gupta, Jeetendra Kumar
    Chanchal, Dilip Kumar
    Shinde, Manoj Gangadhar
    Kumar, Shivendra
    Jain, Divya
    Almarhoon, Zainab M.
    Alshahrani, Asma M.
    Calina, Daniela
    Sharifi-Rad, Javad
    Tripathi, Anjali
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2025, 398 (05) : 4673 - 4687
  • [49] Drug Development Digital Twins for Drug Discovery, Testing and Repurposing: A Schema for Requirements and Development
    An, Gary
    Cockrell, Chase
    FRONTIERS IN SYSTEMS BIOLOGY, 2022, 2
  • [50] The many roles of myeloperoxidase: From inflammation and immunity to biomarkers, drug metabolism and drug discovery
    Siraki, Arno G.
    REDOX BIOLOGY, 2021, 46